RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- Other: Blood sample
- Registration Number
- NCT04575363
- Lead Sponsor
- CHU de Reims
- Brief Summary
PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity.
Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.
- Detailed Description
The aim of this study is to explore the potential implication of RPSA as prognostic biomarker of PDAC.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 90
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description pancreatic adenocarcinoma patient Blood sample patient with pancreatic ductal adenocarcinoma
- Primary Outcome Measures
Name Time Method RPSA serum concentration Day 0 The RPSA serum concentration is assessed with commercially available RPSA ELISA assay (MyBioSource - MBS9137288).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Damien JOLLY
🇫🇷Reims, France